Skip Navigation

Europace 2004 6(2):169-174; doi:10.1016/j.eupc.2003.11.002
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hermida, J.-S.
Right arrow Articles by Schvartz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermida, J.-S.
Right arrow Articles by Schvartz, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias

Jean-Sylvain Hermidaa,*, Emmanuel Tchenga, Genevieve Jarrya, Veronique Moullartb, Sylvie Arlotc, Jean-Luc Reya, Jean Deloncaa and Claire Schvartzd

aCardiology Department, Hôpital Sud, Centre Hospitalier Universitaire, University Hospital 80054 Amiens Cedex, France; bNuclear Medicine Centre, University Hospital Amiens, France; cEndocrinology Department, University Hospital Amiens, France; dBiophysics and Nuclear Medicine Unit, Jean Godinot Institute Reims, France

Amiodarone-induced thyrotoxicosis (AIT) is a common complication of amiodarone therapy. Although permanent withdrawal of amiodarone is recommended due notably to the risk of worsening of tachyarrhythmias, some patients may require the reintroduction of amiodarone several months after normalizing their thyroid function. We, retrospectively, assessed the effects of 131I therapy to prevent recurrence of AIT in euthyroid patients requiring reintroduction of amiodarone.

SUBJECTS AND METHODS: Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M=12, F=3, mean age: 63±14 years). The underlying heart disease was dilated cardiomyopathy (n=4), ischaemic heart disease (n=4), hypertensive heart disease (n=2), arrhythmogenic right ventricular dysplasia (n=2) and valvulopathy (n=1). Two patients had idiopathic paroxysmal AF.

RESULTS: A mean 131I dose of 579±183 MBq was administered 34±37 months after the episode of AIT. Amiodarone was reintroduced in 14 of 15 patients after a mean interval of 103±261 d. Fourteen patients developed definite hypothyroidism necessitating L-thyroxine but we observed no late recurrence of AIT. After a mean follow-up of 22±16 months, tachyarrhythmias were controlled in 12 of 14 patients.

CONCLUSION: 131I therapy appears to be an effective and safe approach to prevent the recurrence of AIT in a patient requiring the reintroduction of amiodarone for tachyarrhythmias.

Key Words: amiodarone, thyrotoxicosis, iodine radioisotope, tachyarrhythmia

*Corresponding author. Tel.: +33-322-45-58-75/+33-614-27-33-09; fax: +33-322-45-56-61/+33-825-17-46-19. E-mail address: hermida.jean-sylvain{at}chu-amiens.fr (J.-S. Hermida).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.